Edgewise Therapeutics (EWTX) Change in Acquisitions & Divestments (2021 - 2026)

Edgewise Therapeutics (EWTX) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 73.56% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $56.4 million (up 301.88% YoY), and the FY2025 full-year result was $67.4 million, up 326.64% from the prior year.
• Change in Acquisitions & Divestments fell to $4.0 million in Q1 2026, from $15.9 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $214.1 million in Q2 2025 to a low of -$258.3 million in Q4 2023.
• A 5-year average of $17.9 million and a median of $36.9 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments plunged 469.69% in 2023 and surged 418.28% in 2025, its largest moves.
• Tracing EWTX's Change in Acquisitions & Divestments over 5 years: stood at $69.9 million in 2022, then sank by 469.69% to -$258.3 million in 2023, then soared by 101.19% to $3.1 million in 2024, then surged by 418.28% to $15.9 million in 2025, then slumped by 75.11% to $4.0 million in 2026.
• Business Quant data shows EWTX's Change in Acquisitions & Divestments at $4.0 million in Q1 2026, $15.9 million in Q4 2025, and -$177.7 million in Q3 2025.